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Abstract 
Alcohol abuse can cause cardiomyopathy indistinguishable from other types of 
dilated non-ischemic cardiomyopathy. Most heavy drinkers remain 
asymptomatic in the earlier stages of disease progression and many never 
develop the ever too familiar clinical manifestations that typify heart failure. We 
will review the current thinking on the pathophysiology, clinical characteristics 
and treatments available for alcoholic cardiomyopathy. The relationship of 
alcohol to heart disease is complicated by the fact that in moderation alcohol has 
been shown to afford a certain degree of protection against cardiovascular 
disease. 
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Introduction 
Alcoholic cardiomyopathy (ICD-10, 142.6) as a unique disease entity has been 
familiar to physicians for close to two centuries. William Mackenzie is credited 
for having coined the term alcoholic heart disease in his treatise titled “Study of the 
pulse” in 19021 . There exist in most societies and all religions, taboos and 
proscriptions pertaining to the use and abuse of alcohol. Nevertheless, references 
to ill effects from excess alcohol usage abound in most societies. Examples 
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include the ‘Tubingen Wine Heart’ described in 1877 and the ‘Munich Beer 
Heart’ as reported by German pathologist Otto Bollinger in 1884 2, 3.  
Using the Alcohol-Related Disease Impact (ARDI) tool, the CDC reports that 
there were approximately 79,000 deaths annually attributable to excessive 
alcohol use (2001–2005) 4.  Furthermore, the rates of excessive drinking and binge 
drinking in young people including college students is concerning 5. Excessive 
alcohol use is the 3rd leading lifestyle-related cause of death for people in the 
United States each year, behind tobacco and improper diet/ lack of physical 
activity which are ranked one and two respectively 6.  
Yet a meta-analysis of 34 prospective studies comprising of over 1 million 
subjects and 10,000 deaths reveals a J shaped relationship between alcohol and 
total mortality as shown in Figure 1 7.  While alcohol consumed in moderation 
may offer protection against cardiovascular events, alcohol abuse can damage 
the heart. Alcohol abuse initially causes asymptomatic left ventricular 
dysfunction but when continued, can cause the ever too familiar signs and 
symptoms of congestive heart failure. Here in, we review current concepts and 
controversies regarding the etiology, pathology and management of patients 
with alcoholic cardiomyopathy. 
Definition and Dose-time Effects 
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Long-term heavy alcohol consumption leading to non-ischemic dilated 
cardiomyopathy is referred to as ‘alcoholic cardiomyopathy’.  Ever since it 
became evident that moderate alcohol consumption has cardio-protective effects 
in normal individuals and those with known heart disease, a matter of great 
debate has been the amount and duration of alcohol abuse required to produce 
detrimental clinical effects. Moderate alcohol consumption (1-2drinks/day) 
decreases cardiovascular and all cause mortality as well as other “hard 
outcomes” including coronary heart disease (CHD), ischemic strokes and 
amputations due to peripheral vascular disease 8.  A study of 490,000 men and 
women found that although all cause mortality increased with heavier drinking, 
moderate drinking reduced cardiovascular mortality especially in middle-aged 
subjects 9. A study of over 10,000 European hypertensive women found evidence 
of reduced risk of CHD and stroke with moderate alcohol consumption 10. A 
recent large meta-analysis of 8 studies consisting of over 16,000 patients with 
cardiovascular disease confirmed that light to moderate alcohol consumption (5 
to 25 g/day) was significantly associated with a decreased incidence of 
cardiovascular and all-cause mortality 11.  Pleiotropic effects of moderate alcohol 
consumption have been proposed to produce this protection against 
cardiovascular events including increased HDL cholesterol, reduced plasma 
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viscosity, decreased fibrinogen concentration, increased fibrinolysis, decreased 
platelet aggregation and coagulation, and enhanced endothelial function 12. 
The potential beneficial effects from alcohol tend to decline as the number of 
drinks consumed per day increases. Although there is a lack of consensus, it 
appears that most alcoholic patients with detectable changes in cardiac structure 
and function report consuming >90 g/day of alcohol for at least 5 years 13-16. It is 
important to note that potential damage to the heart with longstanding alcohol 
abuse is not beverage specific, nor quantity specific, but will vary based on the 
population studied and the individual; genetic and environmental factors and 
types of beverage consumed by a culture or person playing potential roles. 
The CDC estimates that 61.2% of U.S. adults are current drinkers, 14% were 
former drinkers and 5% were classified as heavier drinkers. 17 There are 12 -14 g 
or 0.5-0.6 fl oz of alcohol in a standard drink. A 12 oz bottle of beer, a 4 oz glass 
of wine, and a 1 ½ oz shot of 80-proof spirits all contain the same amount of 
alcohol (one half ounce) as shown in Table 1.  
Each of these is considered a "drink equivalent 18. Mild to moderate alcohol 
consumption has not been shown to be associated with alcoholic 
cardiomyopathy. In fact, data from the Framingham study showed a much lower 
hazard ratio (<0.41) for congestive heart failure in men who imbibed 8-14 
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alcoholic drinks per week indicating a protective effect 19. Moderate alcohol 
consumption was found to lower the risk of heart failure in the Cardiovascular 
Health Study by 34% in patients > 65 years and in the Physician’s Health Study 
by 58% 20, 21. 
Epidemiology 
Reported incidences of alcoholic cardiomyopathy have ranged from 21 percent to 
32 percent of dilated cardiomyopathies in surveys conducted at referral centers, 
but might be higher among patient populations where there is a higher 
frequency of alcoholism 22. Some researchers suggest that at least half of all cases 
of dilated cardiomyopathy are caused by alcohol 23. There also is evidence to 
suspect that the majority of alcoholics are affected by preclinical heart muscle 
disease. Autopsy studies have revealed enlarged hearts and other signs of 
cardiomyopathy in alcoholics who did not show overt symptoms of heart disease 
24.  
Men more commonly develop alcoholic cardiomyopathy, both because more 
men than women drink and do so in greater amounts. But, women consistently 
attain higher maximum blood alcohol concentrations that men for comparable 
levels of alcohol consumption. This is likely due to the greater proportion of 
body water in men and larger proportion of body fat in women 25. The latter 
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results in a slower distribution of alcohol from the blood. Further more women 
have lesser amounts of alcohol metabolizing enzymes such as alcohol and 
aldehyde dehdrogenases 26. Thus, women may develop alcoholic 
cardiomyopathy earlier and at a lower lifetime dose of alcohol  (approximately 
40%) compared to men 27. 
Etiology and Pathophysiology 
It will be difficult to establish a definite causal relationship between heavy 
alcohol consumption and heart failure, given the beneficial effects seen with 
moderate to lower levels of consumption and given the fact that some heavy 
alcohol users never develop overt heart failure.  Nevertheless there are data 
incriminating alcohol in heavy drinkers with asymptomatic and symptomatic left 
ventricular dysfunction (systolic and diastolic). Environmental factors (cobalt, 
arsenic) and genetic predisposition (HLA-B8, alcohol dehydrogenase alleles) 
have been proposed as triggers or abettors in the etio-pathogenesis of alcoholic 
heart disease. For example, ‘Quebec beer-drinkers' cardiomyopathy appeared as 
an epidemic among heavy beer drinkers in Canada in mid-1960s 28. It resembled 
typical a dilated cardiomyopathy except for purplish skin coloration and high 
early mortality rate (42%). This alcoholic cardiomyopathy was associated with 
development of large pericardial effusions and low-output heart failure. ‘Quebec 
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beer-drinkers' cardiomyopathy disappeared when brewers discontinued the 
practice of adding cobalt to beer to stabilize the foam. Cobalt is thought to 
compete with calcium and magnesium leading to inhibition of enzymes involved 
in the metabolism of pyruvate and fatty acids. 29  
Genetic factors can determine how well alcohol is metabolized and can play a 
role in determining the interactions between alcohol and its metabolites and the 
heart. 30For example, polymorphism of the alcohol dehydrogenase type 3 (ADH3) 
gene alters the rate of alcohol metabolism. It has been shown that moderate 
drinkers who are homozygous for the slow-oxidizing ADH3 allele have higher 
HDL levels and a decreased risk of myocardial infarction.31 In contrast, 
polymorphism of the angiotensin converting enzyme (ACE) gene has been 
implicated in alcoholic cardiomyopthy. The ACE DD genotype has been noted to 
increase the likelihood of development of left ventricular dysfunction in 
alcoholics 32.  In contrast to previous beliefs, there is a positive correlation 
between development of alcoholic cardiomyopathy and alcoholic cirrhosis 33. 
Alcohol causes structural and functional changes in the myocardium. Animal 
studies have shown increased myocyte loss (due to apoptosis) in hearts exposed 
to high concentrations of alcohol 34, 35. Ethanol and its metabolites are thought to 
be toxic to the myocyte sarcoplasm and mitochondria 36 37. Alcohol has been 
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shown to have an unfavorable impact on cardiac myofibril shortening and the 
composition of myoproteins 38, 39. Calcium sensitivity at the myofilament level, 
and not altered calcium management, has been shown to produce changes in 
myocardial contractility 40. 
Heavy drinkers have lower ejection fractions, greater end diastolic volumes, 
lower mean fractional shortening and a greater mean left ventricular mass when 
compared with healthy controls in a dose-dependent fashion 27. Such pre-clinical 
abnormalities affecting the left ventricle appear to be independent of nutritional 
status or other habits such as tobacco smoking 41.  
Echocardiographic abnormalities such as increased left atrial dimension, 
increased left ventricular wall thickness and decrease in fractional shortening 
abnormalities precede onset of clinical symptoms or physical findings in heavy 
drinkers 42 Several investigators have reported that diastolic impairment occurs 
commonly and consistently and may precede systolic  dysfunction 43.  Animal 
and some human studies suggest plausible pathophysiologic mechanisms for the 
alterations in systolic and diastolic function seen in alcoholic cardiomyopathy. 
Studies on mice and human tissue have shown that alcohol is a direct myocardial 
toxin and causes ultrastructural damage. This has myriad effects such as edema 
of the sarcoplasmic reticulum, fragmentation of contractile elements, expansion 
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of intercalated disc, and fatty deposits44. Rat cardiomyocytes exposed to alcohol 
have a dose dependant depression in contractility due, at least in part, to a 
depletion of sarcoplasmic calcium 45. Potential pleiotropic mechanisms 
underlying the development of alcoholic cardiomyopathy are shown in Figure #2 
46. 
Clinical features and diagnosis of alcoholic cardiomyopathy 
There exist no unique identifying features that set apart alcoholic 
cardiomyopathy from other causes of heart failure. This diagnosis is further 
complicated by the frequent presence of other risk factors for cardiomyopathy. 
History is key, as is a definite lack of other inciting factors such as certain 
prescribed or non-prescribed drugs (e.g. doxorubicin, cocaine) or ischemic heart 
disease, helps strengthen the diagnosis, which remains one of exclusion. When 
clinically manifest, alcoholic cardiomyopathy demonstrates four chamber 
dilatation, low cardiac output and normal or decreased left ventricular wall 
thickness. Clinical stigmata of heart failure such as a third heart sound, elevated 
jugular venous pulse and cardiomegaly with or without rales may be seen 
especially in decompensated states. The co-existence of liver disease due to 
cirrhosis may give rise to diagnostic confusion when the picture may be less 
straightforward. The association of supraventricular arrhythmias with heavy 
alcohol intake (holiday heart syndrome) as well as an association with sudden 
cardiac death are further complications of alcohol abuse in alcoholic 
cardiomyopathy patients 2, 47, 48. Based on the observations of Fauchier and 
colleagues, the cause of death in patients with alcoholic cardiomyopathy are 
similar to those with idiopathic cardiomyopathy; progressive chronic heart 
 12 
failure and sudden cardiac death 13. Of note, alcoholics with simultaneous 
cardiomyopathy and cirrhosis carry a worse prognosis.49  
Treatment 
There exist no formal guidelines for the treatment of patients with alcoholic heart 
failure.  Multiple studies have shown a tendency towards improvement in left 
ventricular ejection fractions in patients who abstained or drastically decreased 
their intake of alcohol.  A small study of 11 patients reported significant 
improvements in ejection fractions of patients who abstained from alcohol when 
coupled with medical therapy 50 Another study of 55 heavy drinking men 
showed improvement in ejection fractions in those who abstained as well as 
those who controlled drinking (< 60 g of ethanol/day) as shown in Figure 3.51 
Interestingly, in a subset analysis of the Studies of Left Ventricular Dysfunction 
(SOLVD) light to moderate drinkers with ischemic cardiomyopathy had 
significantly lower mortality rates when compared to abstainers 52.  
 
Medical therapy available for alcoholic cardiomyopathy is no different from that 
for other etiologies of heart failure except it should include abstinence from 
alcohol as a cornerstone 53, 54. Survival is poor in those who continue to drink 
heavily with 4-year mortality levels close to 50%. One should follow the heart 
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failure guidelines such as those adopted by the European Society of Cardiology 
or the American College of Cardiology/American Heart Association referenced 
to earlier, that incorporate the use of certain beta-blockers and angiotensin 
converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB). 
Diuretics and digitalis can be used in the management of symptomatic alcoholic 
cardiomyopathy patients. Some of these patients may have co-existing 
nutritional (vitamins, minerals such as selenium or zinc) deficiencies, which may 
need correction as well since they can independently worsen outcomes or 
hamper attempts at treatment. While little data is published regarding the benefit 
of heart transplantation in patients with end-stage alcoholic cardiomyopathy, 
relapse would be a major concern. One study did report alcohol relapse rates 
following liver transplant of 5.6 cases per 100 patient per year for any alcohol use 
and 2.5 cases per 100 patients per year for heavy alcohol use 55. 
Conclusions 
Alcohol in moderation appears to protect against cardiovascular disease. 
However excess use of alcohol results in a type of dilated cardiomyopathy, 
which is indistinguishable from that due to other etiologies of non-ischemic 
cardiomyopthy. Diagnosis remains one of exclusion with strong emphasis on a 
history of heavy alcohol usage. Men are more commonly affected. Asymptomatic 
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impairment of systolic and diastolic functional parameters on echocardiogram is 
increasingly thought to precede the overt manifestation of alcoholic 
cardiomyopathy and is in fact found in the majority of heavy drinkers. Mainstay 
of therapy is abstinence although benefits have been noted even when subjects 
have substantially decreased their intake of alcohol. Medications dictated by 
heart failure guidelines such as beta-blockers, ACEIs and ARBS should be used 
in these patients.  
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Figure legends 
 
FIGURE 1. Relative risk of total mortality (95% confidence interval) and alcohol 
intake extracted from 56 curves using fixed-effects and random-effects models. 
Reprinted with permission from ref#7 
FIGURE 2. Proposed hypothetical schema for the pathogenesis of ACM. gms = 
grams; 
NE = norepinephrine. Reprinted with permission from ref#46 
FIGURE 3. Changes in left ventricular ejection fraction in patients with alcoholic 
cardiomyopathy, according to daily ethanol intake during the first year of the 
study. Group values (squares) are expressed as means; error bars represent 95% 
confidence intervals. Reprinted with permission from ref#50 
 
Table 1. Modified with permission from Department of Agriculture. Provisional Table 
on the Nutrient Content of Beverages. Human Nutrition Information Service. 
Washington, DC, Department of Agriculture. (1982) 
 
 
 
 
